In vivo testing of the therapeutic efficacy of chloroquine on falciparum malaria infections in Chirundu, Mashonaland West, Zimbabwe.
OBJECTIVE
To detect the level of the in vivo chloroquine efficacy in falciparum malaria infections, in order to assess the need for change in the management and treatment of uncomplicated malaria.


METHODS
Prospective descriptive study.


METHODS
Chirundu Rural Clinic, Mashonaland West Province.


METHODS
63 patients confirmed by a positive blood slide for P. falciparum who attended Chirundu clinic, who were eligible for the study and, who also agreed to participate.


METHODS
Frequency of treatment success, early treatment failure and late treatment failure in uncomplicated patients treated with chloroquine.


RESULTS
Out of 63 cases enrolled and completely followed up, chloroquine treatment was effective in 54 cases (85.7%) and was not effective in nine cases (14.3%). All treatment failures were successfully treated with sulphadoxine + pyrimethamine (Fansidar) or quinine following the approved guidelines.


CONCLUSIONS
Chloroquine remains highly effective in the treatment of malaria due to P. falciparum in the Zambezi Valley of Hurungwe district and therefore, has to remain the first line drug. Likewise, guidelines for the use of sulphadoxine + pyrimethamine (Fansidar) or quinine as second line drugs, are adequate to the local situation. Health workers directly supervised the patients when they were swallowing the tablets during the whole course, and this without doubt, indirectly increased the efficacy of chloroquine. It is vital to confirm the malaria diagnosis on the spot appointing microscopists or distributing a limited stock of Parasight-F test.
Barduagni
P
P
Mashonaland West Ministry of Health and Child Welfare, Zimbabwe/Italian Cooperation.
Schwartz
U
U
Nyamayaro
W
W
Chauke
T L
TL
D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000097:blood / Q000627:therapeutic use*; D002648:Child; D002738:Chloroquine / Q000097:blood / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D016778:Malaria, Falciparum / Q000097:blood / Q000188:drug therapy*; D011446:Prospective Studies; D016896:Treatment Outcome; D015030:Zimbabwe
D000962:Antimalarials; D002738:Chloroquine